From needles to pills: oral GLP-1 therapy enters the obesity arena
Abstract Obesity remains a major global health challenge, driving type 2 diabetes, cardiovascular disease, and other complications. Despite effective lifestyle and surgical interventions, pharmacotherapy uptake has historically been limited. Injectable GLP-1 receptor agonists, including semaglutide...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2025-10-01
|
| シリーズ: | Cardiovascular Diabetology. Endocrinology Reports |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s40842-025-00245-5 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|